Celsion Shares Nosedive After Cancer Therapy Fails
Shares of cancer drug developer Celsion (NASDAQ:CLSN) are plunging after the company said its experimental treatment for liver cancer failed in a late-stage human study. The stock which almost quadrupled in the past year dropped 81% to $1.53 in morning trading Thursday. Lawrenceville New Jersey-based Celsion is testing its Thermodox injected drug technology which delivers chemotherapy in what the company hopes is a more targeted approach to killing cancer. Thermodox is being tested for other types of cancer but as a therapy for liver cancer it was in the third and final phase of studies usually needed for US ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here